The arrival of Wegovy, a {semaglutide-based|GLP-1 agonist therapy, in the United Kingdom has prompted thorough evaluation and the creation of specific guidelines for its administration. Current official stance emphasizes that Wegovy is primarily intended for individuals with a body mass index (BMI) of 30 or greater, or those with weight-related ill… Read More